InvestSMART

MGC Pharmaceuticals Ltd (ASX: MXC) - Announcements

Current share price for MXC : $0.420 0.01 (2.44%)+

ASX company news and announcements for MGC Pharmaceuticals Ltd (MXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All MGC Pharmaceuticals Ltd (MXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than MGC Pharmaceuticals Ltd (MXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for MGC Pharmaceuticals Ltd (MXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 MGC PHARMA EXECUTES US$24M US SUPPLY AGREEMENT 27 Aug 2021 8:04AM $0.039 $0.420 risen by 976.92%
$18 Results of General Meeting 13 Aug 2021 8:20AM $0.041 $0.420 risen by 924.39%
$18 General Meeting Web Cast Facility 6 Aug 2021 5:26PM $0.041 $0.420 risen by 924.39%
$18 Notice to Holders of Expiring Options 3 Aug 2021 8:21AM $0.040 $0.420 risen by 950%
$18 Quarterly Activities/Appendix 4C Cash Flow Report 27 Jul 2021 8:22AM $0.040 $0.420 risen by 950%
$18 Response to ASX Query Letter 20 Jul 2021 5:03PM $0.040 $0.420 risen by 950%
$18 Amendment to Appendix 3H lodged 13 July 2021 16 Jul 2021 4:30PM $0.040 $0.420 risen by 950%
$18 PATENT APPLICATION LODGED FOR NOVEL DRUG DELIVERY SYSTEM 15 Jul 2021 7:22PM $0.039 $0.420 risen by 976.92%
$18 Notification of cessation of securities - MXC 13 Jul 2021 6:56PM $0.041 $0.420 risen by 924.39%
$18 s708A(5)(e) Cleansing Notice - Issue of Shares 13 Jul 2021 4:28PM $0.041 $0.420 risen by 924.39%
$18 Application for quotation of securities - MXC 13 Jul 2021 4:27PM $0.041 $0.420 risen by 924.39%
$18 1ST PATIENT RECRUITED INTO CIMETRA PHASE 3 CLINICAL TRIAL 13 Jul 2021 9:29AM $0.038 $0.420 risen by 1,005.26%
$18 Cleansing Notice on Issue of Shares 9 Jul 2021 1:01PM $0.038 $0.420 risen by 1,005.26%
$18 Application for quotation of securities - MXC 9 Jul 2021 12:45PM $0.038 $0.420 risen by 1,005.26%
$18 Notice of General Meeting/Proxy Form 9 Jul 2021 11:28AM $0.038 $0.420 risen by 1,005.26%
$18 CANNEPIL AVAILABLE FOR FREE DISPENSING IN IRELAND 15 Jun 2021 9:38AM $0.048 $0.420 risen by 775%
$18 Issue of shares and resignation of Company Secretary 15 Jun 2021 8:23AM $0.048 $0.420 risen by 775%
$18 Application for quotation of securities - MXC 15 Jun 2021 8:22AM $0.048 $0.420 risen by 775%
$18 Application for quotation of securities - MXC 15 Jun 2021 8:21AM $0.048 $0.420 risen by 775%
$18 Proposed issue of securities - MXC 11 Jun 2021 7:00PM $0.046 $0.420 risen by 813.04%
$18 Company Secretary Appointment 9 Jun 2021 4:12PM $0.047 $0.420 risen by 793.62%
$18 MGC PHARMA 2021 CLINICAL TRIALS PROGRAM UPDATE 25 May 2021 9:20AM $0.049 $0.420 risen by 757.14%
$18 CIMETRA PATENT SUBMITTED TO EUROPEAN IP OFFICE 18 May 2021 9:27AM $0.053 $0.420 risen by 692.45%
$18 Appendix 3G x 3 14 May 2021 4:14PM $0.056 $0.420 risen by 650%
$18 Appendix 2A 14 May 2021 4:06PM $0.054 $0.420 risen by 677.78%

301 - 325 of 818 results

Page 13 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.